PCRC_C30610

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Key Eligibility:

• Histologically or cytologically documented small cell lung cancer (SCLC). Limited-stage disease: Disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes

• Measurable disease, defined as at least one unidimensionally measurable lesion greater than or equal to 2 cm by conventional techniques OR greater than or equal to 1 cm by spiral CT scan

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Patients may have received one and only one course of chemotherapy prior to enrolling on CALGB 30610, which must have included cisplatin and etoposide
Phase III
NCT00632853
Cancer
Lung
Alison Conlin, M.D.
CALGB (Cancer and Leukemia Group B)
Brenda Fisher

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.